Mod GRF 1-29 (CJC-1295 no DAC)
CJC-1295 no DAC (Mod GRF 1-29) 10mg, also known as CJC-1295 no DAC , is a synthetic analogue of Growth Hormone Releasing Hormone (GHRH) developed to replicate and enhance the biological activity of the active fragment of the endogenous hormone. This peptide was born from the scientific observation that the first 29 amino acids of GHRH are responsible for the entire biological function of the complete 44-amino acid molecule. From this discovery, GRF 1-29, or Sermorelin, was born, which, however, exhibited an extremely short half-life due to its high susceptibility to enzymatic degradation. To overcome this limitation, strategic modifications were introduced in the sequence, replacing some amino acids with more stable and cleavage-resistant variants. The result is Mod GRF 1-29, often originally called “tetrasubstituted GRF 1-29”, which today represents one of the most widely used analogues in research to study the physiology of GH thanks to its prolonged half-life and greater receptor affinity
Effects on metabolism, pancreas and diabetes
Several studies have shown that GHRH agonists possess a potential far beyond GH modulation alone. In experimental models, analogues of the GHRH family have shown the ability to promote the proliferation of pancreatic β cells , improving insulin secretion and contributing to more efficient glucose regulation. These results place Mod GRF 1-29 in a particularly interesting area of research for the study of diabetes and conditions requiring functional restoration of pancreatic cells, including islet transplantation, where GHRH agonists appear to improve cell integration and survival.
Reviews
There are no reviews yet.